Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
You may also be interested in...
Former agency heads and outside experts suggest structural reforms in interviews with GAO. Report notes FDA had 10 political appointees in 2020 versus 5 in 2016 and 3 in 2022. House Select Subcommittee on the Coronavirus Crisis describes Trump Administration actions against FDA in its final report.
Agency tells former OOPD director Tim Coté it doesn't have the authority to consider sponsor’s country of origin when determining whether to act on applications. Despite the denial of petition, FDA continues to support Ukraine.
The agency tells former OOPD Director Tim Coté that it does not have the authority to consider the sponsor’s country of origin when determining whether to act on an application.